Literature DB >> 15173885

Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody.

Takao Ando1, Rauf Latif, Terry F Davies.   

Abstract

Thyrotropin receptor (TSHR) Ab's of the stimulating variety are the cause of hyperthyroid Graves disease. MS-1 is a hamster mAb with TSHR-stimulating activity. To examine the in vivo biological activity of MS-1, mice were treated with purified MS-1 intraperitoneally and the thyroid response evaluated. MS-1 induced a dose-dependent increase in serum thyroxine (T4), with a maximum effect after 10 proportional, variant g of MS-1 was administered. MS-1-secreting hybridoma cells were then transferred into the peritoneum of nude mice to study chronic thyroid stimulation. Serum MS-1 levels detected after 2 weeks were approximately 10-50 proportional, variant g/ml, and the serum TSH was suppressed in all animals. Serum triiodothyronine levels were elevated, but only in animals with low serum MS-1 concentrations. In addition, there was a negative correlation between serum T4 and the serum MS-1 concentrations. These in vivo studies suggested a partial TSHR inactivation induced by excessive stimulation by MS-1. We confirmed this inactivation by demonstrating MS-1 modulation of TSHR function in vitro as evidenced by downregulation and desensitization of the TSHR at concentrations of MS-1 achieved in the in vivo studies. Thus, inactivation of the TSHR by stimulating TSHR autoantibodies (TSHR-Ab's) in Graves disease patients may provide a functional explanation for the poor correlation between thyroid function and serum TSHR-Ab concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173885      PMCID: PMC419493          DOI: 10.1172/JCI21334

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Generation of a mouse monoclonal TSH receptor antibody with stimulating activity.

Authors:  S Costagliola; J D F Franssen; M Bonomi; E Urizar; M Willnich; A Bergmann; G Vassart
Journal:  Biochem Biophys Res Commun       Date:  2002-12-20       Impact factor: 3.575

2.  Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.

Authors:  D D Adams; T H Kennedy; R D Stewart
Journal:  Br Med J       Date:  1974-04-27

3.  Clinical and laboratory observations in cases of triiodothyronine toxicosis confirmed by radioimmunoassay.

Authors:  C S Hollander; T Mitsuma; N Nihei; L Shenkman; S Z Burday; M Blum
Journal:  Lancet       Date:  1972-03-18       Impact factor: 79.321

4.  Thyroid-stimulating monoclonal antibodies.

Authors:  Jane Sanders; Jennifer Jeffreys; Hilde Depraetere; Tonya Richards; Michele Evans; Angela Kiddie; Karen Brereton; Marleen Groenen; Yasuo Oda; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Thyroid       Date:  2002-12       Impact factor: 6.568

5.  Human monoclonal thyroid stimulating autoantibody.

Authors:  J Sanders; M Evans; L D K E Premawardhana; H Depraetere; J Jeffreys; T Richards; J Furmaniak; B Rees Smith
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

6.  Value of routine serum-triiodothyronine estimation in diagnosis of thyrotoxicosis.

Authors:  S M Shalet; C G Beardwell; A M Lamb; E Gowland
Journal:  Lancet       Date:  1975-11-22       Impact factor: 79.321

7.  Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.

Authors:  N Kuzuya; S C Chiu; H Ikeda; H Uchimura; K Ito; S Nagataki
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

8.  Thyrotropin (TSH)-induced receptor internalization in nonthyroidal cells transfected with a human TSH-receptor complementary deoxyribonucleic acid.

Authors:  N E Heldin; B Gustavsson; A Hermansson; B Westermark
Journal:  Endocrinology       Date:  1994-05       Impact factor: 4.736

9.  Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs.

Authors:  E D Mukhtar; B R Smith; G A Pyle; R Hall; P Vice
Journal:  Lancet       Date:  1975-03-29       Impact factor: 79.321

10.  Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.

Authors:  R Docter; G Bos; T J Visser; G Hennemann
Journal:  Clin Endocrinol (Oxf)       Date:  1980-02       Impact factor: 3.478

View more
  10 in total

1.  When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?

Authors:  Suyeon Park; Eyun Song; Hye-Seon Oh; Mijin Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Doo Man Kim; Won Bae Kim
Journal:  Endocrine       Date:  2019-06-24       Impact factor: 3.633

2.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

Authors:  Chris J van Koppen; Marcel E de Gooyer; Willem-Jan Karstens; Ralf Plate; Paolo G M Conti; Tanja A E van Achterberg; Monique G A van Amstel; Jolanda H G M Brands; Jesse Wat; Rob J W Berg; J Robert D Lane; Andre M M Miltenburg; C Marco Timmers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  A unique mouse strain that develops spontaneous, iodine-accelerated, pathogenic antibodies to the human thyrotrophin receptor.

Authors:  Basil Rapoport; Holly A Aliesky; Bianca Banuelos; Chun-Rong Chen; Sandra M McLachlan
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

4.  Biased signaling by thyroid-stimulating hormone receptor-specific antibodies determines thyrocyte survival in autoimmunity.

Authors:  Syed A Morshed; Risheng Ma; Rauf Latif; Terry F Davies
Journal:  Sci Signal       Date:  2018-01-23       Impact factor: 8.192

Review 5.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

6.  Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades.

Authors:  Syed A Morshed; Takao Ando; Rauf Latif; Terry F Davies
Journal:  Endocrinology       Date:  2010-09-15       Impact factor: 4.736

7.  Chronic exposure in vivo to thyrotropin receptor stimulating monoclonal antibodies sustains high thyroxine levels and thyroid hyperplasia in thyroid autoimmunity-prone HLA-DRB1*0301 transgenic mice.

Authors:  Jeffrey C Flynn; Jacqueline A Gilbert; Chady Meroueh; Daniel P Snower; Chella S David; Yi-chi M Kong; J Paul Banga
Journal:  Immunology       Date:  2007-05-29       Impact factor: 7.397

8.  Characterization of thyrotropin receptor antibody-induced signaling cascades.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Endocrinology       Date:  2008-08-21       Impact factor: 4.736

9.  Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.

Authors:  Monica A Ercolano; Monica L Drnovsek; Maria C Silva Croome; Monica Moos; Ana M Fuentes; Fanny Viale; Ulla Feldt-Rasmussen; Alicia T Gauna
Journal:  Thyroid Res       Date:  2013-09-11

10.  In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70).

Authors:  Jadwiga Furmaniak; Jane Sanders; Stuart Young; Katarzyna Kabelis; Paul Sanders; Michele Evans; Jill Clark; Jane Wilmot; Bernard Rees Smith
Journal:  Auto Immun Highlights       Date:  2011-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.